Full Press Release Details
PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data for D-PLEX100 will be highlighted in a podium presentation at the first triennial International Orthopaedic Trauma Association meeting being held on December 14-16, 2022, at the RAI Amsterdam Exhibition and Conference Center in Amsterdam, The Netherlands.
First Triennial Meeting of the International Orthopaedic Trauma Association:
| Presentation Title: | Surgical wound infection reduction with locally administered product releasing doxycycline - Implications for orthopaedic trauma injuries |
| Presenter: | Noam Emanuel, PhD., Chief Scientific Officer, PolyPid Ltd. |
| Date/Time: | Thursday, December 15, 2022, Infection, wound treatment Session, 8:00 a.m. – 9:00 a.m., room E-108 |
The abstract will be available on www.polypid.com once the conference concludes.